Innovations in Regenerative Biomaterials. $MDXG
Marietta, GA
Joined October 2014
- Tweets446
- Following1
- Followers857
- Likes7
Today we announced operating and financial results for Q2 2023, with net sales up more than 20% year-over-year in consecutive quarters! Read more in the release and join our webcast today at 5:00 p.m. ET for all the latest updates: bit.ly/3DBJCyO
Join the MIMEDX leadership team for our second quarter 2023 operating and financial results conference call on August 1. All the details + webcast information available here: bit.ly/44MugDk
Today at 5:00 p.m. ET, our leadership team will cover operating and financial results for Q1 2023—our strongest start in several years, highlighted by nearly 22% growth in net sales year-over-year. Read more and stream the webcast here: bit.ly/3VniTyd
If you're attending the @MohsCollege annual meeting this year, be sure to stop by booth #100 to learn about placental-based allografts and their use in Mohs surgery. See you next week! #ACMS2023 #Mohssurgery
Join the MIMEDX leadership team for our first quarter 2023 operating and financial results conference call on May 2. All the details + webcast information available here: bit.ly/3A4UrYG
The Office of Inspector General has recently published a report detailing the need for pricing transparency in Medicare’s reimbursement of skin substitutes in the private physician office setting. Read more about our support for these findings: bit.ly/3mTzLzs
Today, we announced our operating and financial results for Q4 & FY 2022, which included the Company’s highest quarterly net sales since Q4 2019. Read more and join our webcast for all the latest updates: bit.ly/3ZrjnUH
Join the MIMEDX leadership team for our Q4 & FY 2022 operating and financial results conference call on February 28. All the details + webcast information available here: bit.ly/3IpLmhS
Please join us in welcoming Joe Capper as CEO at MIMEDX! An accomplished MedTech and Life Sciences executive, Joe joins with nearly 30 years of experience to lead our efforts to advance the science and innovate the field of placental biologics. Read more: bit.ly/3HKqUYJ
Today, MIMEDX reaffirmed fourth quarter and full year 2022 net sales expectations and provided corporate updates, including commentary on the evolving Medicare reimbursement landscape. View the press release for the latest details: bit.ly/3VQobAU
Today, we announced significant progress in our international market expansion with the commercial launch of EPIFIX® in Japan and an exclusive distribution agreement with GUNZE Medical. Read more: bit.ly/3Gh6WmH
The MIMEDX team wishes you and yours a magical holiday season that’s merry and bright! #HappyHolidays #Merry #Bright
We are pleased to announce an agreement with Turn Therapeutics to accelerate our product development pipeline with a proprietary antimicrobial technology platform. Learn more: bit.ly/3UJ7Hdj
We’re back in NYC for the @Piper_Sandler 34th Annual Healthcare Conference! Live stream the event to see MIMEDX senior management present recent highlights: bit.ly/3iqT9kX
Today, we’re presenting at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in NYC. Tune in to the webcast at 9:30 a.m. ET: bit.ly/3Oa7kqD
Today, we honor all of our U.S. Armed Forces veterans for their service. With appreciation, we thank you.
Join us in-person or stream online as our leadership team participates in two investor conferences this month. For all the details visit: bit.ly/3DVqDPM
Reminder: Today at 5:00 p.m. ET, the MIMEDX senior management team will discuss Q3 2022 operating and financial results. Join us for a live webcast here: bit.ly/3NCfkAs $MDXG
The MIMEDX senior management team will present Q3 2022 operating and financial results on Wednesday, November 2 at 5:00 p.m. ET. Full details: bit.ly/3TgMGqk $MDXG
